The Impact of Immunogenicity on Therapeutic Antibody Pharmacokinetics: A Preclinical Evaluation of the Effect of Immune Complex Formation and Antibody Effector Function on Clearance

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2021 Nov 12

PMID 34763611

Citations 4

Authors

Eugenia Opolka-Hoffmann

Gregor Jordan

Michael Otteneder

Robin Kieferle

Martin Lechmann

Gerhard Winter

Roland F Staack

Affiliations

Soon will be listed here.

Abstract

The occurrence of an immune response against therapeutic proteins poses a major risk for the development of biologics and for successful treatment of patients. Generation of anti-drug antibodies (ADAs) can lead to formation of immune complexes (ICs), consisting of drug and ADAs, with potential impact on safety, efficacy and exposure. Here, we focus on the effects of IC formation, i.e., specific IC sizes, ADA and drug properties, on drug pharmacokinetics. Pre-formed IC preparations of an IgG drug (with wild type or with an ablated effector function at the Fc domain) and different ADA surrogates (directed against the complementarity-determining regions or Fc domain of the drug) were administered to rats and collected serum was analyzed to determine the total drug concentration. A combination of size-exclusion chromatography and ELISA enabled a size-specific evaluation of IC profiles in serum and their changes over time. Within five minutes, total drug concentration decreased by ~20-60% when the drug was complexed. Independent of the ADA surrogate and drug variant used, increasing IC size led to increased clearance. Comparing ICs formed with the same ADA surrogate but different IgG variants, we observed that complexed drug with a wildtype Fc domain showed faster clearance compared to immune effector function modified drug. Data generated in this study indicated that clearance of drug due to ADA generation is driven by size and structure of the formed ICs, but also by the immune effector functions of the Fc domains of IgGs. Ab: antibody, ADA: anti-drug antibody, AUC: area under the curve, Bi: biotin, CDR: complementary-determining region, c: maximal concentration, Dig: digoxigenin, ELISA: enzyme-linked immunosorbent assay, Fc: fragment crystallizable, FcRn: neonatal Fc receptor, HMW: high molecular weight, IC: immune complex, IC-QC: immune complex quality control, IgG: immunoglobulin G, mAb: monoclonal antibody, mADA: monoclonal ADA, pAb: polyclonal antibody, pADA: polyclonal ADA, PD: pharmacodynamics; PK: pharmacokinetic, QC: quality control, SEC: size-exclusion chromatography, WT: wildtype.

Citing Articles

Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn's disease patients.

Genaro L, Carron J, de Castro M, Franceschini A, Lourenco G, Cruz C Int J Immunopathol Pharmacol. 2025; 39:3946320251319379.

PMID: 39959979 PMC: 11831650. DOI: 10.1177/03946320251319379.

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.

Spreafico A, Munoz Couselo E, Irmisch A, Bessa J, Au-Yeung G, Bechter O Front Oncol. 2024; 14:1346502.

PMID: 38577337 PMC: 10991832. DOI: 10.3389/fonc.2024.1346502.

Biodistribution of Drug/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution.

Opolka-Hoffmann E, Edelmann M, Otteneder M, Hauri S, Jordan G, Schrag P AAPS J. 2024; 26(2):33.

PMID: 38478197 DOI: 10.1208/s12248-024-00899-6.

Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice.

Egli J, Heiler S, Weber F, Steiner G, Schwandt T, Bray-French K MAbs. 2022; 14(1):2143009.

PMID: 36394299 PMC: 9673943. DOI: 10.1080/19420862.2022.2143009.

Pre-Clinical In-Vitro Studies on Parameters Governing Immune Complex Formation.

Fichter M, Richter G, Bepperling A, Wassmann P Pharmaceutics. 2022; 14(6).

PMID: 35745826 PMC: 9227392. DOI: 10.3390/pharmaceutics14061254.

References

Salimi-Moosavi H, Lee J, DeSilva B, Doellgast G . Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. J Pharm Biomed Anal. 2009; 51(5):1128-33. DOI: 10.1016/j.jpba.2009.11.021. View

Regula J, Lundh von Leithner P, Foxton R, Barathi V, Cheung C, Tun S . Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016; 8(11):1265-1288. PMC: 5090659. DOI: 10.15252/emmm.201505889. View

Diebolder C, Beurskens F, de Jong R, Koning R, Strumane K, Lindorfer M . Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014; 343(6176):1260-3. PMC: 4250092. DOI: 10.1126/science.1248943. View

Rojko J, Evans M, Price S, Han B, Waine G, DeWitte M . Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies. Toxicol Pathol. 2014; 42(4):725-64. DOI: 10.1177/0192623314526475. View

van Schie K, Kruithof S, Ooijevaar-De Heer P, Derksen N, van de Bovenkamp F, Saris A . Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies. Ann Rheum Dis. 2018; 77(10):1471-1479. DOI: 10.1136/annrheumdis-2018-213299. View

Klein C, Schaefer W, Regula J . The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs. 2016; 8(6):1010-20. PMC: 4968094. DOI: 10.1080/19420862.2016.1197457. View

Lo M, Kim H, Tong R, Bainbridge T, Vernes J, Zhang Y . Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. J Biol Chem. 2017; 292(9):3900-3908. PMC: 5339770. DOI: 10.1074/jbc.M116.767749. View

Mousavi S, Sporstol M, Fladeby C, Kjeken R, Barois N, Berg T . Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcgammaRIIb2. Hepatology. 2007; 46(3):871-84. DOI: 10.1002/hep.21748. View

Chirmule N, Jawa V, Meibohm B . Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012; 14(2):296-302. PMC: 3326159. DOI: 10.1208/s12248-012-9340-y. View

10.

Rojas J, Taylor R, Cunningham M, Rutkoski T, Vennarini J, Jang H . Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005; 313(2):578-85. DOI: 10.1124/jpet.104.079277. View

11.

Heinrich J, Staack R, Stubenrauch K, Papadimitriou A . Proposal for a harmonized descriptive analyte nomenclature for quantitative large-molecule bioanalysis. Bioanalysis. 2015; 7(24):3057-62. DOI: 10.4155/bio.15.218. View

12.

Ritter G, Cohen L, WILLIAMS Jr C, Richards E, Old L, Welt S . Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 2001; 61(18):6851-9. View

13.

Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

14.

Staack R, Stracke J, Stubenrauch K, Vogel R, Schleypen J, Papadimitriou A . Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. Bioanalysis. 2011; 3(5):523-34. DOI: 10.4155/bio.11.16. View

15.

Schlothauer T, Herter S, Koller C, Grau-Richards S, Steinhart V, Spick C . Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016; 29(10):457-466. DOI: 10.1093/protein/gzw040. View

16.

Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J . Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol. 2009; 54(2):164-82. DOI: 10.1016/j.yrtph.2009.03.012. View

17.

Hoffmann E, Jordan G, Lauer M, Ringler P, Kusznir E, Rufer A . Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies. Pharm Res. 2019; 36(9):129. PMC: 6598957. DOI: 10.1007/s11095-019-2661-0. View

18.

van Schouwenburg P, Bartelds G, Hart M, Aarden L, Wolbink G, Wouters D . A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010; 362(1-2):82-8. DOI: 10.1016/j.jim.2010.09.005. View

19.

Finbloom D, Plotz P . Studies of reticuloendothelial function in the mouse with model immune complexes. II. Serum clearance, tissue uptake, and reticuloendothelial saturation in NZB/W mice. J Immunol. 1979; 123(4):1600-3. View

20.

Bogers W, Stad R, Janssen D, van Rooijen N, van Es L, Daha M . Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells. Clin Exp Immunol. 1991; 86(2):328-33. PMC: 1554119. DOI: 10.1111/j.1365-2249.1991.tb05818.x. View